Table 1.
Characteristics of HER2-positive patients
| No (%) of patients
| |||
|---|---|---|---|
| Characteristics | Total
|
Trastuzumab+
|
Trastuzumab−
|
| 717 | 258 | 459 | |
| Patient age (years) | |||
| ≤35 | 65 (9.1) | 33 (12.8) | 32 (7.0) |
| 36–50 | 278 (38.8) | 116 (45.0) | 162 (35.3) |
| >50 | 374 (52.2) | 109 (42.2) | 265 (57.7) |
| Tumor size (mm) | |||
| ≤20 | 246 (34.3) | 87 (33.7) | 159 (34.6) |
| 21–50 | 383 (53.4) | 135 (52.3) | 248 (54) |
| >50 | 56 (7.8) | 31 (12.0) | 25 (5.4) |
| Unknown | 32 (4.5) | 5 (1.9) | 27 (5.9) |
| Cancer stage | |||
| DCIS | 21 (2.9) | 0 (0.0) | 21 (4.6) |
| I | 176 (24.5) | 58 (22.5) | 118 (25.7) |
| II | 418 (58.3) | 151 (58.5) | 267 (58.2) |
| III | 102 (14.2) | 49 (19.0) | 53 (11.5) |
| LN status | |||
| 0 | 459 (64.0) | 153 (59.3) | 306 (66.7) |
| 1–3 | 122 (17.0) | 55 (21.3) | 67 (14.6) |
| ≥4 | 127 (17.7) | 49 (19.0) | 78 (17.0) |
| Unknown | 9 (1.3) | 1 (0.4) | 8 (1.7) |
| Histologic grade | |||
| I–II | 311 (43.4) | 122 (47.3) | 189 (41.2) |
| II–III | 75 (10.5) | 34 (13.2) | 41 (8.9) |
| III | 132 (18.4) | 49 (19.0) | 83 (18.1) |
| Unknown and DCIS | 199 (27.8) | 53 (20.5) | 146 (27.8) |
| Embolus | |||
| Yes | 160 (22.3) | 78 (30.2) | 82 (17.9) |
| No | 351 (49.0) | 114 (44.2) | 237 (51.6) |
| Unknown | 206 (28.7) | 66 (25.6) | 140 (30.5) |
| NCT | |||
| Yes | 139 (19.4) | 64 (24.8) | 75 (16.3) |
| No | 578 (80.6) | 194 (75.2) | 384 (83.7) |
| Chemotherapy | |||
| No | 92 (12.8) | 5 (1.9) | 87 (19.0) |
| Anthracycline-based | 194 (27.1) | 36 (14.0) | 158 (34.4) |
| Taxane | 418 (58.3) | 217 (84.1) | 201 (43.8) |
| Others | 7 (1.0) | 0 (0.0) | 7 (1.5) |
| Unknown | 6 (0.8) | 0 (0.0) | 6 (1.3) |
| History of mother suffered BC | |||
| Yes | 46 (6.4) | 18 (7.0) | 28 (6.1) |
| No | 671 (93.6) | 240 (93.0) | 431 (93.9) |
| Menopause | |||
| Yes | 367 (51.2) | 117 (45.3) | 250 (54.5) |
| No | 350 (48.8) | 141 (54.7) | 209 (45.5) |
| Sex hormone receptor | |||
| Positive | 398 (55.5) | 134 (51.9) | 264 (57.5) |
| Negative | 319 (44.5) | 124 (48.1) | 195 (42.5) |
| Endocrine therapy | |||
| Yes | 370 (51.6) | 130 (50.4) | 240 (52.3) |
| No | 324 (45.2) | 119 (46.1) | 205 (44.7) |
| Unknown | 23 (3.2) | 9 (3.5) | 14 (3.1) |
| Radiotherapy | |||
| Yes | 299 (41.7) | 151 (58.5) | 148 (32.3) |
| No | 411 (57.3) | 106 (41.1) | 305 (66.4) |
| Unknown | 7 (1.0) | 1 (0.4) | 6 (1.3) |
| Ki-67 (%) | |||
| ≤14 | 123 (17.2) | 49 (19.0) | 74 (16.1) |
| >14 | 258 (36.0) | 113 (43.8) | 145 (31.6) |
| Unknown | 336 (46.9) | 96 (37.2) | 240 (52.3) |
| BMI (kg/m2) | |||
| <18.5 | 26 (3.6) | 8 (3.1) | 18 (3.9) |
| 18.5–23.9 | 389 (54.3) | 142 (55.0) | 247 (53.8) |
| ≥24 | 290 (40.4) | 104 (40.3) | 186 (40.5) |
| Unknown | 12 (1.7) | 4 (1.6) | 8 (1.7) |
Abbreviations: BC, breast cancer; BMI, body mass index; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; LN, lymph node; NCT, neoadjuvant chemotherapy.